

10522 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

C o n t e n t s

	<u>Page</u>
DIGEST	1
CHAPTER	
1 INTRODUCTION	7
2 LIMITED ENFORCEMENT OF COMPLIANCE WITH GOOD MANUFACTURING PRACTICES	11
Limited use of legal sanctions to enforce GMP compliance	12
Reasons for infrequent use of legal sanctions	17
Lack of adequate guidelines	17
Therapeutic insignificance of nonprescription drugs	19
Need for embargo authority	20
Slow judicial process	20
Recent steps toward more aggres- sive enforcement	20
Conclusion	21
Recommendation to the Secretary of Health, Education, and Welfare	21
3 NEED FOR MORE CORRECTIVE FOLLOWUP ACTIONS	23
Post inspection communication of findings	24
Followup inspections	25
Post inspection letters to drug producers eliminated by policy statement	27
Conclusion	29
Recommendation to the Secretary of Health, Education, and Welfare	29
4 SOME DRUG PRODUCERS NOT INSPECTED AS OFTEN AS REQUIRED	30
Firms subject to inspection	30
Types of firms not inspected and prior deviations	32
Reasons given for not inspecting all drug producers	33
Conclusions	35